125 related articles for article (PubMed ID: 38504270)
21. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
[TBL] [Abstract][Full Text] [Related]
22. Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase.
Kinnaird A; Dromparis P; Saleme B; Gurtu V; Watson K; Paulin R; Zervopoulos S; Stenson T; Sutendra G; Pink DB; Carmine-Simmen K; Moore R; Lewis JD; Michelakis ED
Eur Urol; 2016 Apr; 69(4):734-744. PubMed ID: 26433571
[TBL] [Abstract][Full Text] [Related]
23. An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma.
Zarrabi K; Wu S
Expert Opin Biol Ther; 2018 Jun; 18(6):695-705. PubMed ID: 29782188
[TBL] [Abstract][Full Text] [Related]
24. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
25. Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma.
Dumond A; Brachet E; Durivault J; Vial V; Puszko AK; Lepelletier Y; Montemagno C; Pagnuzzi-Boncompagni M; Hermine O; Garbay C; Lagarde N; Montes M; Demange L; Grépin R; Pagès G
J Exp Clin Cancer Res; 2021 Jan; 40(1):33. PubMed ID: 33461580
[TBL] [Abstract][Full Text] [Related]
26. Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy.
Labbate C; Hatogai K; Werntz R; Stadler WM; Steinberg GD; Eggener S; Sweis RF
J Immunother Cancer; 2019 Mar; 7(1):66. PubMed ID: 30857555
[TBL] [Abstract][Full Text] [Related]
27. Targeting the transcription factor receptor LXR to treat clear cell renal cell carcinoma: agonist or inverse agonist?
Wu G; Wang Q; Xu Y; Li J; Zhang H; Qi G; Xia Q
Cell Death Dis; 2019 May; 10(6):416. PubMed ID: 31138790
[TBL] [Abstract][Full Text] [Related]
28. Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma.
Tachibana H; Kondo T; Ishihara H; Fukuda H; Yoshida K; Takagi T; Izuka J; Kobayashi H; Tanabe K
Jpn J Clin Oncol; 2021 Apr; 51(4):646-653. PubMed ID: 33212488
[TBL] [Abstract][Full Text] [Related]
29. Endosialin-positive tumor-derived pericytes promote tumor progression through impeding the infiltration of CD8
Lu T; Zhang J; Lu S; Yang F; Gan L; Wu X; Song H; Liu S; Xu C; Han D; Yang B; Wen W; Qin W; Yang L
Cancer Immunol Immunother; 2023 Jun; 72(6):1739-1750. PubMed ID: 36646951
[TBL] [Abstract][Full Text] [Related]
30. Integrative Analysis of the Genomic and Immune Microenvironment Characteristics Associated With Clear Cell Renal Cell Carcinoma Progression: Implications for Prognosis and Immunotherapy.
Lin E; Zhu P; Ye C; Huang M; Liu X; Tian K; Tang Y; Zeng J; Cheng S; Liu J; Liu Y; Yu Y
Front Immunol; 2022; 13():830220. PubMed ID: 35677048
[TBL] [Abstract][Full Text] [Related]
31. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
Laccetti AL; Garmezy B; Xiao L; Economides M; Venkatesan A; Gao J; Jonasch E; Corn P; Zurita-Saavedra A; Brown LC; Kao C; Kinsey EN; Gupta RT; Harrison MR; Armstrong AJ; George DJ; Tannir N; Msaouel P; Shah A; Zhang T; Campbell MT
Cancer Med; 2021 Apr; 10(7):2341-2349. PubMed ID: 33650321
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma.
Farolfi A; Schepisi G; Conteduca V; Burgio SL; Lolli C; De Giorgi U
Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1089-96. PubMed ID: 27450183
[TBL] [Abstract][Full Text] [Related]
33. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
[TBL] [Abstract][Full Text] [Related]
34. CXC chemokine receptor 2 is associated with postoperative recurrence and survival of patients with non-metastatic clear-cell renal cell carcinoma.
An H; Xu L; Chang Y; Zhu Y; Yang Y; Chen L; Lin Z; Xu J
Eur J Cancer; 2015 Sep; 51(14):1953-61. PubMed ID: 26188847
[TBL] [Abstract][Full Text] [Related]
35. A New Signature That Predicts Progression-Free Survival of Clear Cell Renal Cell Carcinoma with Anti-PD-1 Therapy.
Lin J; Cai Y; Ma Y; Pan J; Wang Z; Zhang J; Liu Y; Zhao Z
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982415
[TBL] [Abstract][Full Text] [Related]
36. BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma.
Labadie BW; Liu P; Bao R; Crist M; Fernandes R; Ferreira L; Graupner S; Poklepovic AS; Duran I; Maleki Vareki S; Balar AV; Luke JJ
J Transl Med; 2019 Nov; 17(1):386. PubMed ID: 31767020
[TBL] [Abstract][Full Text] [Related]
37. Nicotinamide-N-methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma.
Reustle A; Menig LS; Leuthold P; Hofmann U; Stühler V; Schmees C; Becker M; Haag M; Klumpp V; Winter S; Büttner FA; Rausch S; Hennenlotter J; Fend F; Scharpf M; Stenzl A; Bedke J; Schwab M; Schaeffeler E
Clin Transl Med; 2022 Jun; 12(6):e883. PubMed ID: 35678045
[TBL] [Abstract][Full Text] [Related]
38. Immune cell mediated cabozantinib resistance for patients with renal cell carcinoma.
Park KY; Hefti HO; Liu P; Lugo-Cintrón KM; Kerr SC; Beebe DJ
Integr Biol (Camb); 2021 Dec; 13(11):259-268. PubMed ID: 34931665
[TBL] [Abstract][Full Text] [Related]
39. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.
Suarez ER; Chang de K; Sun J; Sui J; Freeman GJ; Signoretti S; Zhu Q; Marasco WA
Oncotarget; 2016 Jun; 7(23):34341-55. PubMed ID: 27145284
[TBL] [Abstract][Full Text] [Related]
40. Synergistic antitumor responses by combined GITR activation and sunitinib in metastatic renal cell carcinoma.
Yu N; Fu S; Xu Z; Liu Y; Hao J; Zhang A; Wang B
Int J Cancer; 2016 Jan; 138(2):451-62. PubMed ID: 26239999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
